Transcatheter aortic valve replacement (TAVR) was as safe, effective, noninferior, and even superior to surgical aortic valve replacement in patients with severe aortic stenosis who were at low risk of death from surgery, demonstrated a pair of trials in the New England Journal of Medicine. TAVR is currently only indicated for patients at high risk of surgical complications.
